Skip to main content
. 2018 Nov 20;23(11):3030. doi: 10.3390/molecules23113030

Figure 2.

Figure 2

Combined maritoclax and TRAIL treatment induces caspase-dependent apoptosis. (A) Caki cells were treated with 50 ng/mL TRAIL in the presence or absence of 2 μM maritoclax for 24 h. Caspase activities were determined using caspase-3 DEVDase assay kits. (B) Caki cells were treated with 2 μM maritoclax plus 50 ng/mL TRAIL for 24 h in the presence or absence of 20 μM z-VAD-fmk (zVAD). The sub-G1 fraction was measured by flow cytometry. The protein expression levels were determined by Western blotting. (C) Caki cells were treated with indicated concentrations of maritoclax for 24 h. The protein expression levels were determined by Western blotting. The band intensity of the proteins was measured using ImageJ (public domain JAVA image-processing program; http://rsb.info.nih.gov/ij). −, no treatment; +, treatment. The values in graph (A,B) represent the mean ± SD from three independent samples. * p < 0.01 compared to the control. # p < 0.01 compared to maritoclax plus TRAIL by ANOVA and Student-Newman-Keuls methods.